Georges Azzi, MD

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.

Georges Azzi, MD, discusses the unmet needs the Signatera circulating tumor DNA assay could fulfill in colorectal cancer.

Georges Azzi, MD, discusses the rationale for the phase 3 CIRCULATE study in colorectal cancer.

Georges Azzi, MD, discusses the utility of the Signatera circulating tumor DNA assay as a preferred test in colorectal cancer (CRC).